IP Library › Granted Patent US 7,803,824
Granted Patent B2
US 7,803,824 · App. 11/394,893 · Granted Sep 28, 2010

Use of inhibitors of Jun N-terminal kinases to treat glaucoma

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,824
App. No.
11/394,893
Granted
Sep 28, 2010
Kind
B2
Abstract

Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection.

Claims (3)

1. A method for decreasing ocular hypertension, which comprises administering to a human patient identified as having glaucoma a composition comprising an effective amount of a JNK inhibitor and a pharmaceutically acceptable vehicle, wherein the JNK inhibitor is

2. A method according to claim 1 , wherein the composition is an oral formulation.

3. A method according to claim 1 , wherein the composition is a topical ophthalmic, surgical irrigating solution or an intraocular formulation.

Assignments (2)
MERGER Recorded May 31, 2011
From: ALCON, INC.
To: NOVARTIS AG
Reel/Frame 026376/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2006
From: FLEENOR, DEBRA L.; PANG, IOK-HOU
To: ALCON, INC.
Reel/Frame 017715/0387 →